Upregulation of PD-L1 in cancer cells can be attributed to oncogenic signaling pathways that involve the deletion or silencing of phosphatase tensin homologs (PTEN), constitutive anaplastic lymphoma kinase (ALK), and EGFR 2, 80. The gene discussed is PTEN; the disease is cancer.